Next, we demonstrated that metothrexate therapy in JIA patients did not affect levels of CD34 + CD309+ cells (0.02% [0.007%-0.08%] vs. 0.03% [0.003%-0.31%]; p = 0.92, for JIA patients with and without MTX, respectively) (Figure 2c). The gene discussed is CD34; the disease is juvenile idiopathic arthritis.